TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27779436

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 543
Study: 27779572

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin-mycophenolate mofetil-tacrolimus protocol
Number of subjects: 51
Study: 27780238

Group type: EXPERIMENTAL
Intervention: Cellulitis cases with lower extremity blisters
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Abscess cases with methicillin-resistant S. aureus (MRSA) colonization
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Microbiome analysis of cellulitis aspirates
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Microbiome evaluation of aspirate specimens
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Microbiome evaluation of abscess specimens
Number of subjects: 201
Study: 27780778

Group type: EXPERIMENTAL
Intervention: Resting state functional connectivity using 7T fMRI
Number of subjects: 32
Study: 27780903

Group type: EXPERIMENTAL
Intervention: Successful reperfusion (defined as modified Treatment in Cerebral Ischemia grade of 2b to 3)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Thrombi retrieved from the reperfused group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Atheromatous gruel
Number of subjects: 83

Group type: COMPARATOR
Intervention: >64% erythrocyte components
Number of subjects: 83
Study: 27781135

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1-3 mg/day
Number of subjects: 37
Study: 27781241

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectum excision (TME) with guidance of membrane anatomy
Number of subjects: 0
Study: 27781342

Group type: EXPERIMENTAL
Intervention: Early satiety (ES) severity
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Postprandial fullness (PPF) severity
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with other symptoms
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with gastroparesis severity
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with BMI
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with quality of life
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with gastric retention
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with water load test
Number of subjects: 198
Study: 27782373

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/simeprevir plus flat dose ribavirin (800 mg/d) for 12 weeks
Number of subjects: 270
Study: 27782769

Group type: EXPERIMENTAL
Intervention: Self-reports on the Screener and Opioid Assessment for Patients with Pain®-Revised questionnaire
Number of subjects: 2171

Group type: COMPARATOR
Intervention: Investigator assessment
Number of subjects: 2171

Group type: EXPERIMENTAL
Intervention: Self-reports on the Self-Reported Misuse, Abuse, and Diversion questionnaire
Number of subjects: 2171

Group type: EXPERIMENTAL
Intervention: Current Opioid Misuse Measure
Number of subjects: 2171

Group type: EXPERIMENTAL
Intervention: Urine drug tests (UDTs)
Number of subjects: 2171
Study: 27782854

Group type: EXPERIMENTAL
Intervention: Genotype-matched trials
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Genotype-unmatched trials
Number of subjects: 1640
Study: 27783381

Group type: EXPERIMENTAL
Intervention: Acute respiratory failure with pneumonia etiology
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Acute respiratory failure with non-infectious diagnoses
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Acute respiratory failure with opportunistic infection
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Acute respiratory failure with undetermined etiology
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Overall hospital mortality in patients with ARF
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Invasive pulmonary aspergillosis
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Use of invasive mechanical ventilation
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: SOFA score >7
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Undetermined ARF etiology
Number of subjects: 604
Study: 27783539

Group type: EXPERIMENTAL
Intervention: CAPTURE with PEF
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control subjects (not specified intervention)
Number of subjects: 346
Study: 27784272

Group type: EXPERIMENTAL
Intervention: Baseline examinations including biochemistry, 24-h Holter ECG recordings, 24-h ambulatory blood pressure measurement, 24-h pulse wave analysis and pulse wave velocity, retinal vessel analysis, and neurocognitive testing.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Follow-up examinations after 24 months including biochemistry, single PWA, single PWV, and neurocognitive testing.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Follow-up for up to 6 years for hospitalizations, cardiovascular events, non-cardiovascular events, cardiovascular mortality, and all-cause mortality.
Number of subjects: 500
Study: 27784331

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 0
Study: 27784746

Group type: EXPERIMENTAL
Intervention: CRLX101
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRLX101 and 5-fluorouracil
Number of subjects: 0
Study: 27784751

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole
Number of subjects: 61
Study: 27784821

Group type: EXPERIMENTAL
Intervention: Severe chronic hyperglycemia (>42 mmol/mol)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Severe chronic hyperglycemia (>42 mmol/mol) after adjustment for confounding factors
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Moderate chronic hyperglycemia (39-42 mmol/mol)
Number of subjects: 812
Study: 27785036

Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS) with sensor-embedded tablets of aripiprazole, 8-week treatment.
Number of subjects: 67
Study: 27786499

Group type: EXPERIMENTAL
Intervention: Instrumental message
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Empowering message
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Presence of mediator measures
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: No mediator measures
Number of subjects: 722
Study: 27787664

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-free treatment
Number of subjects: 3474
Study: 27787778

Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5 mg and 25 mg doses)
Number of subjects: 2639

Group type: COMPARATOR
Intervention: Sulfonylurea (SU)
Number of subjects: 2639
Study: 27788018

Group type: EXPERIMENTAL
Intervention: Impact of Events Scale-Revised
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-Traumatic Stress Symptoms instrument
Number of subjects: 0
Study: 27788131

Group type: EXPERIMENTAL
Intervention: UV-induced DNA damage
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Endogenous DNA damage
Number of subjects: 2
Study: 27788856

Group type: EXPERIMENTAL
Intervention: Renal Denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Procedure
Number of subjects: 0
Study: 27788880

Group type: EXPERIMENTAL
Intervention: pnfC1-INH (20 IU/kg per HAE attack)
Number of subjects: 46
Study: 27789021

Group type: EXPERIMENTAL
Intervention: Engineered autologous nasal chondrocyte-based cartilage grafts
Number of subjects: 10
Study: 27789145

Group type: EXPERIMENTAL
Intervention: LAIV3 in children
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IIV3 in adults
Number of subjects: 44

Group type: COMPARATOR
Intervention: LAIV3 in adults
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IIV3 and LAIV3 in children and adults
Number of subjects: 44
Study: 27789147

Group type: EXPERIMENTAL
Intervention: Pfs25H-EPA/Alhydrogel® vaccine candidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct skin feeding assay (DSF)
Number of subjects: 0
Study: 27789517

Group type: EXPERIMENTAL
Intervention: Adenosine diphosphate receptor inhibitors (ADPri) therapy
Number of subjects: 11858

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 11858

Group type: EXPERIMENTAL
Intervention: Bare metal stents
Number of subjects: 11858

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 11858

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11858

Group type: EXPERIMENTAL
Intervention: Early cessation of ADPri therapy
Number of subjects: 11858
Study: 27789541

Group type: EXPERIMENTAL
Intervention: PwMS
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PwCIS
Number of subjects: 105

Group type: COMPARATOR
Intervention: HS
Number of subjects: 105
Study: 27789678

Group type: EXPERIMENTAL
Intervention: INCB039110 (selective JAK1 inhibitor)
Number of subjects: 0
Study: 27790041

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight fraction of 5% human serum albumin (LMWF-5A)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 329
Study: 27790201

Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27790729

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus simeprevir ± ribavirin
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 240
Study: 27790763

Group type: EXPERIMENTAL
Intervention: 300IR dose of allergen extract daily, by sublingual route
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 27791054

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High ELS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low ELS
Number of subjects: 0
Study: 27791128

Group type: EXPERIMENTAL
Intervention: Vaccination with peptide 1
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Vaccination with peptide 1 or 7 in combination with RFASE
Number of subjects: 2

Group type: COMPARATOR
Intervention: Antibodies raised with peptides 15 and 20
Number of subjects: 2
Study: 27791347

Group type: EXPERIMENTAL
Intervention: PF-06651600 (JAK3-selective inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: JAK3-selective inhibition
Number of subjects: 0
Study: 27792655

Group type: EXPERIMENTAL
Intervention: Corrected QT interval (QT)
Number of subjects: 93
Study: 27792656

Group type: EXPERIMENTAL
Intervention: Prasugrel with PPI
Number of subjects: 11955

Group type: EXPERIMENTAL
Intervention: Clopidogrel with PPI
Number of subjects: 11955

Group type: EXPERIMENTAL
Intervention: Prasugrel without PPI
Number of subjects: 11955

Group type: EXPERIMENTAL
Intervention: Clopidogrel without PPI
Number of subjects: 11955

Group type: COMPARATOR
Intervention: PPI use
Number of subjects: 11955
Study: 27792741

Group type: COMPARATOR
Intervention: TTR<65%
Number of subjects: 9934

Group type: EXPERIMENTAL
Intervention: TTR≥65%
Number of subjects: 9934
Study: 27793100

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Postprandial glucose
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose, postprandial glucose, and HbA1c
Number of subjects: 427
Study: 27793105

Group type: EXPERIMENTAL
Intervention: Monitoring of regional cerebral saturation of oxygen using pediatric cerebral sensors
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Monitoring of mean arterial blood pressure (MAP) and pulse oximetry (SpO2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Gestation as a possible risk factor
Number of subjects: 43
Study: 27793162

Group type: EXPERIMENTAL
Intervention: iBreastExam (iBE) performed by a trained ultrasound technician
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 78
Study: 27793850

Group type: EXPERIMENTAL
Intervention: DMUC5754A (0.3-3.2 mg/kg every 3 weeks)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DMUC5754A (0.8-1.6 mg/kg weekly)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DMUC5754A (Q3W)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DMUC5754A (Q1W)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DMUC5754A
Number of subjects: 77
Study: 27794402

Group type: EXPERIMENTAL
Intervention: MAGE-A3
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: PRAME
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Both MAGE-A3 and PRAME
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: At least one TAA (MAGE-A3 or PRAME)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Squamous cell carcinomas
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 377
Study: 27794406

Group type: EXPERIMENTAL
Intervention: Interdisciplinary palliative care intervention including care planning and education sessions for patients and FCGs
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study: 27795367

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 6
Study: 27795384

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27795599

Group type: EXPERIMENTAL
Intervention: Positive Thoughts and Actions (PTA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Individual Support Program (ISP)
Number of subjects: 120
Study: 27796252

Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Gratitude
Number of subjects: 156
Study: 27796540

Group type: EXPERIMENTAL
Intervention: Elotuzumab monotherapy (10 or 20 mg/kg)
Number of subjects: 31
Study: 27796740

Group type: EXPERIMENTAL
Intervention: ASP0113 (5 mg, five doses at intervals before and after HCT)
Number of subjects: 10
Study: 27796820

Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Choline-positron emission tomography-computed tomography (choline-PET/CT)
Number of subjects: 35
Study: 27797317

Group type: EXPERIMENTAL
Intervention: Systematic workup for pulmonary embolism including low pretest clinical probability and negative d-dimer assay.
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Computed tomographic pulmonary angiography or ventilation-perfusion lung scanning for patients without low pretest clinical probability and negative d-dimer assay.
Number of subjects: 560

Group type: COMPARATOR
Intervention: Patients with alternative explanation for syncope.
Number of subjects: 560

Group type: COMPARATOR
Intervention: Patients without alternative explanation for syncope.
Number of subjects: 560
Study: 27797889

Group type: EXPERIMENTAL
Intervention: Sustained microalbuminuria
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Remitted microalbuminuria
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 1441
Study: 27797979

Group type: EXPERIMENTAL
Intervention: Pacemaker implantation for high-risk patients (≥70 ms HV interval)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Loop recorder device with remote monitoring for lower-risk patients (HV <70 ms)
Number of subjects: 200
Study: 27797988

Group type: EXPERIMENTAL
Intervention: 10-month physical activity programme combined with a normocaloric diet
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 10-month physical activity programme
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Normocaloric diet
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combination of physical activity and normocaloric diet
Number of subjects: 68
Study: 27798002

Group type: EXPERIMENTAL
Intervention: Genetic variants associated with CLBP
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Glycomics profiles associated with CLBP
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Activomics profiles associated with CLBP
Number of subjects: 12000
Study: 27798032

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 3741
Study: 27798339

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 39
Study: 27798342

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs) concentration measurement using LC-mass spectrometry
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Secretor milk samples from Malawi
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fucosylated HMOs in secretor milk samples from Malawi
Number of subjects: 133
Study: 27798346

Group type: EXPERIMENTAL
Intervention: Night-fasting intervals (mean ± SD: 9.9 ± 1.6 h)
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Daily eating episodes (mean ± SD: 4.2 ± 1.3 times/d)
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Night-fasting intervals
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Daily eating episodes
Number of subjects: 1061
Study: 27798550

Group type: EXPERIMENTAL
Intervention: 600 mg of TDF during labor (Cohort 1)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 4 mg/kg dose on days 0, 3 and 5 (Cohort 2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 900 mg maternal dose during labor, followed by 6 mg/kg infant dose on days 0, 3 and 5 (Cohort 3)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall cohort of HIV-exposed infants
Number of subjects: 89
Study: 27799048

Group type: EXPERIMENTAL
Intervention: EBRT in 23 fractions of 2 Gy and HDR in 3 fractions of 6.5 Gy
Number of subjects: 118
Study: 27799138

Group type: EXPERIMENTAL
Intervention: Technology-based injury prevention program with anticipatory guidance
Number of subjects: 308

Group type: COMPARATOR
Intervention: Relevant booklet on parenting
Number of subjects: 308
Study: 27799204

Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz (single oral dose)
Number of subjects: 73
Study: 27799230

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration for 7 days
Number of subjects: 287
Study: 27799506

Group type: EXPERIMENTAL
Intervention: Dabrafenib and NovoTTF-100A (Tumor Treatment Fields device)
Number of subjects: 1

Group type: COMPARATOR
Intervention: NovoTTF-100A (Tumor Treatment Fields device) with concurrent radiation and chemotherapy (CCRT)
Number of subjects: 1
Study: 27799945

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a fixed dose of 0.033 mg/kg/day for 260 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a fixed dose of 0.067 mg/kg/day for 260 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (both doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (high dose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 80
Study: 27800159

Group type: EXPERIMENTAL
Intervention: Case management (CM)
Number of subjects: 0
Study: 27801315

Group type: EXPERIMENTAL
Intervention: JAK inhibitor ruxolitinib
Number of subjects: 0
Study: 27801983

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (most common type of glucocorticoid)
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Hydrocortisone dosing frequency
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Various regimens for hydrocortisone
Number of subjects: 1166
Study: 27802497

Group type: EXPERIMENTAL
Intervention: Obese participants with normoglycemia (n=5)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Obese participants with prediabetes (n=9)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Obese participants with diabetes (n=9)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lean controls (n=2)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 102
Study: 27802546

Group type: EXPERIMENTAL
Intervention: Type VII collagen gene-corrected grafts (approximately 35 cm2) transplanted onto 6 wounds in each patient (n=24 grafts).
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Type VII collagen gene-corrected grafts.
Number of subjects: 4
Study: 27803005

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg daily
Number of subjects: 18
Study: 27803036

Group type: EXPERIMENTAL
Intervention: IMR>40
Number of subjects: 283

Group type: COMPARATOR
Intervention: IMR>40 and CFR≤2.0
Number of subjects: 283
Study: 27803138

Group type: EXPERIMENTAL
Intervention: Subcutaneous Golimumab (GOL) 50 mg or 100 mg every 4 weeks
Number of subjects: 2867

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2867
Study: 27803655

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation at point ST36
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control point CP1 (same dermatome)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control point CP2 (different dermatome)
Number of subjects: 0
Study: 27803954

Group type: EXPERIMENTAL
Intervention: Femoral closure (Angio-Seal™, St. Jude Medical, Inc.)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Radial compression (TR Band)
Number of subjects: 400
Study: 27805836

Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor (200 mg lumacaftor/250 mg ivacaftor orally every 12 hours for 24 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor
Number of subjects: 58
Study: 27806864

Group type: EXPERIMENTAL
Intervention: Reward-based spatial learning task
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control condition (unexpected rewards)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Learning condition (expected rewards)
Number of subjects: 27
Study: 27806964

Group type: EXPERIMENTAL
Intervention: Milrinone protocol following S1P
Number of subjects: 32

Group type: COMPARATOR
Intervention: Best clinical judgment prior to protocol implementation
Number of subjects: 32
Study: 27806978

Group type: EXPERIMENTAL
Intervention: Body composition reference curves for preterm infants generated using air-displacement plethysmography (ADP) and lambda-mu-sigma method for percentile estimation.
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Body composition reference charts for total FM and FFM at birth in preterm infants.
Number of subjects: 223
Study: 27807285

Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931); chronic treatment in rats and monkeys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931); single and multiple doses in healthy human subjects and AD patients
Number of subjects: 0
Study: 27807306

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0